JPRN-UMIN000028468已完成未知
Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarker - Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarker
orst East Japan Study Group(NEJSG)0 个研究点目标入组 60 人开始时间: 2017年8月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Having history of immuno-checkpoint-inhibitor 2.Having history of autoimune disease 3.Having active or symptomatic interstitial lung disease 4.With infections requiring systemic treatment 5.Having symptomatic brain metastasis 6.Having poorly controlled diabetes 7.Having active liver disease 8.Having history of severe hypersensitivity 9.Patient judged inappropriate by the attending physician
研究者
相似试验
进行中（未招募）
2 期
Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarkerJPRN-jRCTs031180013Kagamu Hiroshi60
已完成
2 期
A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Study10027412pleural mesotheliomaNL-OMON41970Antoni van Leeuwenhoek Ziekenhuis33
进行中（未招募）
不适用
ivolumab in patients with progressive malignant pleural mesothelioma: NivoMesA single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes StudyMedDRA version: 17.1Level: LLTClassification code 10027408Term: Mesothelioma malignant advancedSystem Organ Class: 100000004864EUCTR2014-003935-20-NLStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
进行中（未招募）
1 期
Phase II Study of Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in Patients with Locally Advanced/ Metastatic Squamous Cell Carcinoma of the SkiCTIS2024-513637-20-00Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH61
招募中
2 期
Phase II Study of Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in Patients with Locally Advanced/ Metastatic Squamous Cell Carcinoma of the Skin2024-513637-20-00Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH61